Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F20%3A00533049" target="_blank" >RIV/67985823:_____/20:00533049 - isvavai.cz</a>
Result on the web
<a href="https://www.liebertpub.com/doi/10.1089/ars.2020.8024" target="_blank" >https://www.liebertpub.com/doi/10.1089/ars.2020.8024</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1089/ars.2020.8024" target="_blank" >10.1089/ars.2020.8024</a>
Alternative languages
Result language
angličtina
Original language name
Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism
Original language description
Recent Advances: The noncanonical activation of NRF2 was recently discovered, and members of this pathway are involved in carcinogenesis. Further, cancer-related changes (e.g., metabolic flexibility) that support cancer progression were found to be redox- and NRF2 dependent.nCritical Issues: NRF2 undergoes Janus-faced behavior in cancers. The pro- or antineoplastic effects of NRF2 are context dependent and essentially based on the specific molecular characteristics of the cancer in question. Therefore, systematic investigation of NRF2 signaling is necessary to clarify its role in cancer etiology. The biggest challenge in the NRF2 field is to determine which cancers can be targeted for better clinical outcomes. Further, large-scale genomic and transcriptomic studies are missing to correlate the clinical outcome with the activity of the NRF2 system.nFuture Directions: To exploit NRF2 in a clinical setting in the future, the druggable members of the NRF2 pathway should be identified. In addition, it will be important to study how the modulation of the NRF2 system interferes with cytostatic drugs and their combinations.n
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/NV19-01-00101" target="_blank" >NV19-01-00101: Pancreatic cancer: metabolic derangements assiocated with insulin resistance</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Antioxidants & Redox Signaling
ISSN
1523-0864
e-ISSN
—
Volume of the periodical
33
Issue of the periodical within the volume
13
Country of publishing house
US - UNITED STATES
Number of pages
32
Pages from-to
966-997
UT code for WoS article
000525301800001
EID of the result in the Scopus database
2-s2.0-85086841484